Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma

Tools

Item Type:	Article
Title:	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma
Creators Name:	Han, Y., Lindner, S., Bei, Y., Garcia, H.D., Timme, N., Althoff, K., Odersky, A., Schramm, A., Lissat, A., Künkele, A., Deubzer, H.E., Eggert, A., Schulte, J.H. and Henssen, A.G.
Abstract:	Medulloblastoma is the most prevalent central nervous system tumor in children. Targeted treatment approaches for patients with high-risk medulloblastoma are needed as current treatment regimens are not curative in many cases and cause significant therapy-related morbidity. Medulloblastoma harboring MYC amplification have the most aggressive clinical course and worst outcome. Targeting the BET protein BRD4 has significant anti-tumor effects in preclinical models of MYC-amplified medulloblastoma, however, in most cases these are not curative. We here assessed the therapeutic efficacy of the orally bioavailable BRD4 inhibitor, MK-8628, in preclinical models of medulloblastoma. MK-8628 showed therapeutic efficacy against in vitro and in vivo models of MYC-amplified medulloblastoma by inducing apoptotic cell death and cell cycle arrest. Gene expression analysis of cells treated with MK-8628 showed that anti-tumor effects were accompanied by significant repression of MYC transcription as well as disruption of MYC-regulated transcriptional programs. Additionally, we found that targeting of MYC protein stability through pharmacological PLK1 inhibition showed synergistic anti-medulloblastoma effects when combined with MK-8628 treatment. Thus, MK-8628 is effective against preclinical high-risk medulloblastoma models and its effects can be enhanced through simultaneous targeting of PLK1.
Keywords:	BRD4, MYC, PLK1, Pediatric Brain Tumors, Targeted Therapy, Animals, Mice
Source:	Cancer Letters
ISSN:	0304-3835
Publisher:	Elsevier
Volume:	445
Page Range:	24-33
Date:	31 March 2019
Official Publication:	https://doi.org/10.1016/j.canlet.2018.12.012
PubMed:	View item in PubMed

Repository Staff Only: item control page